Powered by BIO-IMS: Transforming preventive medicine by detecting biochemical shifts at just 100 cells.
Questions? Send us an email
info@kidodscience.com
Ultra-sensitive molecular tracking to identify oral pathogens before localized or systemic escalation occurs.
Deep molecular mapping of STIs and complex flora imbalances, capturing microbial micro-shifts at inception.
Instantly differentiating overlapping metabolic signatures of chronic and acute conditions like COPD, Asthma, and TB.
Detecting malignant cellular mutations when they are just 100 cells small—years before physical tumors form.
This test has not yet approved by the U.S. Food and Drug Administration (FDA)
Diseases begin years before the first symptom appears. BIO-IMS is Kidod’s proprietary platform technology engineered to detect abnormal metabolic shifts at the molecular level – identifying cellular abnormalities when they are just 100 cells small.
Our BIO-IMS platform is currently being deployed across four critical clinical domains to transform diagnostic timelines:
Oral Pathogen Tracking: Detecting infectious oral diseases before systemic escalation.
Advanced Gynecological Screening: Mapping STIs, Vaginosis, and complex vaginal flora micro-shifts at inception.
Precision Respiratory Analysis: Isolating the distinct biochemical signatures of COPD, Asthma, Pneumonia, and Tuberculosis.
Early-Stage Oncology Interception: Identifying cancer-related cellular abnormalities at the pre-tumor phase.
Discover how Kidod is shaping the future of early disease detection.
To transform global healthcare by enabling the earliest detection of disease through comprehensive molecular analysis. We empower clinicians, elevate patient outcomes, and advance true preventive medicine for communities worldwide.
